Filtered By:
Specialty: Dermatology
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 964 results found since Jan 2013.
Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts
In conclusion, specific c-Abl gene silencing using siRNA effectively reduced fibrosis-related gene expression. Inhibition of c-Abl by siRNA may be a potential therapeutic approach for fibrotic diseases such as systemic sclerosis.
Source: Archives of Dermatological Research - December 20, 2014 Category: Dermatology Source Type: research
Novel nanosome delivery system combined with siRNA targeting the antimicrobial gene DFB4: A new approach for psoriasis management?
This study encourages the exploration of topical gene silencing strategies in dermatology, and refocuses our attention on both, the role of hBD2 in psoriasis pathogenesis, and the thorny question which animal model reflects human psoriasis most faithfully.
This article is protected by copyright. All rights reserved.
Source: Experimental Dermatology - March 28, 2014 Category: Dermatology Authors: A Keren, M David, A Gilhar Tags: Commentary from the Editorial Board Source Type: research
Allele-specific sirna corrects aberrant cellular phenotype in keratitis-ichthyosis-deafness syndrome keratinocytes
Keratitis-ichthyosis-deafness (KID) syndrome is a severe, untreatable condition characterized by ocular, auditory and cutaneous abnormalities, with major complications of infection and skin cancer. 86% of cases are caused by a heterozygous missense mutation (c.148G>A, p.D50N) in the GJB2 gene, encoding gap junction protein connexin 26 (Cx26), which alters gating properties of Cx26 channels in a dominant manner. We hypothesized that a mutant-allele-specific siRNA (AS-siRNA) could rescue the cellular phenotype in patient keratinocytes.
Source: Journal of Investigative Dermatology - November 5, 2019 Category: Dermatology Authors: Ming Yang Lee, Hong-Zhan Wang, Thomas W. White, Tony Brooks, Alan Pittman, Heerni Halai, Anastasia Petrova, Diane Xu, Stephen L. Hart, Veronica A. Kinsler, Wei-Li Di Tags: Original Article Source Type: research
1092 Topical delivery of siRNA therapeutics into the skin using STAR particles
Small interfering RNA (siRNA) therapeutics offer promising gene silencing of disease targets in various tissues. Unlike traditional small molecules, siRNAs can be chemically optimized to target a particular tissue or cell type. This scaffold can then be reprogrammed with different target sequences for treatment of a wide array of genetically defined diseases. Unfortunately, topical delivery of macromolecules such as siRNA molecules into the skin is physically impaired by the stratum corneum barrier.
Source: Journal of Investigative Dermatology - April 17, 2023 Category: Dermatology Authors: M. Zain Ul Abideen, Q. Tang, H. Fakih, K. Gross, R. Furgal, C. Blanchard, C. Bouix-peter, T. Portal, A. Khvorova, J.E. Harris, J. Alterman Source Type: research
532 siRNA based non-viral gene therapy for the treatment of epidermolysis bullosa simplex(EBS)
EBS is an inherited, skin fragility disorder predominantly caused by dominant-negative mutations in genes encoding for the cytoskeletal proteins, Keratin5 and Keratin14 within the basal cell layer. To date, EBS is incurable with only symptomatic therapies currently available. The downregulation of these mutant genes would provide an excellent curative therapy for treating EBS. siRNA therapeutics have been identified as an attractive therapy option for EBS given the highly accessible nature of skin tissue.
Source: Journal of Investigative Dermatology - April 12, 2017 Category: Dermatology Authors: J. O'Keeffe Ahern, D. Zhou, L. Cutlar, I. Lara-S áez, W. Wang Tags: Genetic Disease, Gene Regulation and Gene Therapy Source Type: research
478 Mutation-specific siRNA Knockdown of GJB2 − Potential gene therapy for Keratitis-ichthyosis-deafness Syndrome
Mutations in the GJB2 gene, which encodes connexin 26 (Cx26), cause keratitis-ichthyosis-deafness (KID) syndrome. 87% of patients carry a dominant mutation D50N, which is thought to cause a dominant negative effect on the normal allele product. Current treatment is limited to symptomatic care. We hypothesised that a mutation-specific siRNA to selectively suppress the D50N mutant allele may potentially reverse the disease phenotype. We first tested whether suppression of a single Cx26 allele can lead to haplo-insufficiency in human keratinocytes (KCs).
Source: Journal of Investigative Dermatology - April 12, 2017 Category: Dermatology Authors: M. Lee, V.A. Kinsler, S.L. Hart, W. Di Tags: Genetic Disease, Gene Regulation and Gene Therapy Source Type: research
Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study.
CONCLUSION: Inverse correlation between therapeutic delay and clinical response was found, supporting early adalimumab use and providing evidence for a "window of opportunity" in HS. Adalimumab efficacy and safety were confirmed, along with patients' QoL improvement. Immunosuppressants could negatively influence response to adalimumab inducing a switch to non-TNFα -driven pathways.
PMID: 32119111 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - March 1, 2020 Category: Dermatology Authors: Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, Sirna R, Gisondi P, Patrizi A, Dini V, Bianchini D, Bianchi L, Fania L, Prignano F, Offidani A, Atzori L, Bettoli V, Cannavò SP, Venturini M, Bongiorno MR, Costanzo A, Fabbrocini G, Peri Tags: Br J Dermatol Source Type: research
801 Novel nanoparticles mediate efficient siRNA/mRNA co-delivery to melanoma
Checkpoint immunotherapy has revolutionized treatment for patients with advanced or metastatic melanoma; however, many patients ’ tumors either fail to respond or develop secondary resistance. As a result, there is an urgent need for an off-the-shelf local treatment that can improve therapeutic outcomes by increasing immune activation and reducing immunosuppressive factors. We developed a library of novel lipophilic poly(b eta-amino ester) (PBAE)-based biodegradable nanoparticle (NP) formulations with different backbone, sidechain, and endcap monomers and various lipophilic/linear ratios to efficiently co-deliver mRNA an...
Source: Journal of Investigative Dermatology - April 17, 2023 Category: Dermatology Authors: K.M. Luly, E.E. Rocher, J.J. Green, S.Y. Tzeng, J.C. Sunshine Source Type: research
Dual oxidase 2 is essential for house dust mite‐induced pro‐inflammatory cytokine production in human keratinocytes
This article is protected by copyright. All rights reserved.
Source: Experimental Dermatology - July 1, 2015 Category: Dermatology Authors: Eunbi Ko, Hyun Choi, Kkot‐Nara Park, Ju‐Yearl Park, Tae Ryong Lee, Dong Wook Shin, Yun Soo Bae Tags: Regular Article Source Type: research
Adiponectin Upregulates Filaggrin Expression via SIRT1-Mediated Signaling in Human Normal Keratinocytes.
CONCLUSION: Adiponectin upregulates FLG expression through a SIRT1-mediated pathway. Our results suggest that Acrp30 is a promising agent for skin barrier permeability improvement.
PMID: 28761287 [PubMed]
Source: Annals of Dermatology - August 2, 2017 Category: Dermatology Tags: Ann Dermatol Source Type: research
Safety and Efficacy of TGF- β1/COX-2 Silencing Therapeutic in Adults With Cutaneous Squamous Cell Carcinoma In Situ
J Drugs Dermatol. 2022 May 1;21(5):472-477. doi: 10.36849/JDD.6384.ABSTRACTThis single-center, open label, dose escalation cohort study evaluated the safety and efficacy of various doses of intralesional injections of TGF-β1/COX-2 combined with histidine-lysine polypeptide (siRNA/HKP) nanoparticle silencing therapeutic in patients with cutaneous in situ squamous cell carcinoma. Twenty-five patients (mean age: 67, SD: 10 years; 52% men) with cutaneous in situ squamous cell carcinoma participated. TGF-β1/COX-2 siRNA/HKP nanoparticle therapeutic was injected weekly for up to 6 weeks based on the following do...
Source: Journal of Drugs in Dermatology - May 9, 2022 Category: Dermatology Authors: Mark Nestor Brian Berman Patrick Lu Michael Molyneaux Source Type: research
